Progentec Diagnostics, Inc.
Our Story Our Research Publications Progentec Presents News
Technology Product Pipeline The aiSLE® DX Family of Tests [AutoimmuneCorner]™ LupusCorner® Research LupusCorner®
Team Board of Directors Advisors Careers
Partner With Us Contact Us
Patient Support
Progentec Research Technologies
About our Laboratory Tests We Offer Order our tests
About Our Story Our Research Publications Progentec Presents News Technologies Technology Product Pipeline The aiSLE® DX Family of Tests [AutoimmuneCorner]™ LupusCorner® Research LupusCorner® Team Team Board of Directors Advisors Careers Partner with Us Partner With Us Contact Us For Patients Patient Support R&D Services Progentec Research Technologies Progentec Lab Services About our Laboratory Tests We Offer Order our tests
Progentec Diagnostics, Inc.
Proteomics and digital health for the proactive care of systemic lupus erythematosus, multiple sclerosis (MS), and autoimmune diseases

IFN-β treatment requires B cells for efficacy in neuroautoimmunity

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4340715/

Schubert RD, Hu Y, Kumar G, et al. IFN-β treatment requires B cells for efficacy in neuroautoimmunity. J Immunol. 2015;194(5):2110-2116. doi:10.4049/jimmunol.1402029

Multiple SclerosisAdminOctober 6, 2025Publication
Facebook0 Twitter LinkedIn0
Previous

Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL

Multiple SclerosisAdminOctober 6, 2025Publication
Next

Cytokine profiles show heterogeneity of interferon-b response in multiple sclerosis patients

Multiple SclerosisAdminOctober 6, 2025Publication
Keep up with Progentec!

 
 

 
progentec-logo-web.png
 

755 Research Parkway, Suite #100, Oklahoma City, OK 73104


Phone: 833-587-8739 EXT 110
Fax: 833.335.3314


info@progentec.com

 
Hours
 

Copyright Progentec Diagnostics, Inc. 2022 All rights reserved

Privacy Policy | Terms & Conditions | Conflict of Interest Policy